Revision as of 16:05, 22 January 2023 edit2600:1700:407b:2810:6015:d9d0:4a7d:d0ae (talk) →Good Evidence for Antineoplaston Efficacy from Japan: ReplyTag: Reply← Previous edit | Latest revision as of 10:49, 31 December 2024 edit undoHob Gadling (talk | contribs)Extended confirmed users18,443 edits remove botched section | ||
(122 intermediate revisions by 39 users not shown) | |||
Line 1: | Line 1: | ||
{{Talk header|search=yes |
{{Talk header|search=yes}} | ||
{{Controversial}} | |||
{{User:MiszaBot/config | |||
{{Not a forum}} | |||
|archiveheader = {{aan}} | |||
{{WikiProject banner shell|blp=yes|class=B|1= | |||
|maxarchivesize = 100K | |||
{{WikiProject Skepticism|importance=Mid|needs-infobox=no}} | |||
|counter = 8 | |||
{{WikiProject Medicine|importance=Low|infobox-requested=no|needs-photo=Yes}} | |||
|minthreadsleft = 8 | |||
{{WikiProject Alternative medicine}} | |||
|algo = old(90d) | |||
{{WikiProject United States|importance=Low|TX=yes|TX-importance=Low|needs-infobox=no|image-needed=Yes|map-needed=no|geocoord-needed=No|image-in=Texas|map-in=Texas}} | |||
|archive = Talk:Burzynski Clinic/Archive %(counter)d | |||
}} | }} | ||
{{User:HBC Archive Indexerbot/OptIn | |||
|target=/Archive index |mask=/Archive <#> |leading_zeros=0 |indexhere=yes | |||
}} | |||
{{WikiProject banner shell|blp=yes|1= | |||
{{WikiProject Skepticism|class=B|importance=Mid|needs-infobox=Yes}} | |||
{{WikiProject Medicine|class=B|importance=Low|infobox-requested=Yes|needs-photo=Yes}} | |||
{{WikiProject Alternative medicine|class=B}} | |||
{{WikiProject United States|class=B|importance=Low|TX=yes|TX-importance=Low|needs-infobox=Yes|image-needed=Yes|map-needed=Yes|geocoord-needed=No|image-in=Texas|map-in=Texas}} | |||
}} | |||
{{off topic warning}} | |||
{{controversial}} | |||
{{Copied |from=Burzynski Clinic |from_oldid=509758461 |to=Stanislaw Burzynski |to_diff=509759041 |to_oldid=509730018 |date=12:03, 29 August 2012}} | |||
{{ArbComPseudoscience}} | |||
{{Press | {{Press | ||
| subject = article | | subject = article | ||
Line 31: | Line 18: | ||
| accessdate = January 29, 2020 | | accessdate = January 29, 2020 | ||
}} | }} | ||
{{Copied |from=Burzynski Clinic |from_oldid=509758461 |to=Stanislaw Burzynski |to_diff=509759041 |to_oldid=509730018 |date=12:03, 29 August 2012}} | |||
__TOC__ | |||
{{ArbComPseudoscience}} | |||
{{User:MiszaBot/config | |||
== missing source == | |||
|archiveheader = {{aan}} | |||
|maxarchivesize = 100K | |||
|counter = 8 | |||
|minthreadsleft = 8 | |||
|algo = old(90d) | |||
|archive = Talk:Burzynski Clinic/Archive %(counter)d | |||
}} | |||
{{User:HBC Archive Indexerbot/OptIn | |||
|target=/Archive index |mask=/Archive <#> |leading_zeros=0 |indexhere=yes | |||
}} | |||
__TOC__ | |||
please give a source for this statement: | |||
"there is no clinical evidence of the efficacy of these methods" ] (]) 16:53, 21 August 2021 (UTC) | |||
:See the article, where it says "''The Memorial Sloan-Kettering Cancer Center has stated: "Bottom Line: There is no clear evidence to support the anticancer effects of antineoplastons in humans.''" and the reference there that supports it. The rest of the article has multiple refs many of which support the fact. Thanks. -] ] 16:58, 21 August 2021 (UTC) | |||
== Good Evidence for Antineoplaston Efficacy from Japan == | |||
That reference does not support what is written in the article. If that's what the reference says, then say that. There is "clinical evidence of efficacy", but I suppose what you consider a reputable source of the operative determination so it is should be "there are no FDA approved clinical evidence" or something to that effect based on the reference article. ] (]) 10:10, 15 January 2023 (UTC) | |||
:It's not just the FDA (some administration in some random country), it is the scientific community that counts. --] (]) | |||
A 2015 study from Ogata et al. titled "<u>Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer</u>" (https://doi.org/10.1371/journal.pone.0120064) records that in an open label, non-blinded but randomized phase II study '''cancer specific survival rate (CSS) was significantly higher in the antineoplaston arm vs. the control (i.e. non-antineoplaston) arm.''' This study had 65 patients enrolled, with 33 of those in the control group not receiving antineoplaston therapy, and 32 receiving the treatment. Median survival in the antineoplaston group, was, in fact, 67 months vs. 39 months, with a CSS of 60% and 32%, respectively. Furthermore, there were no incidental serious toxicities or apparent liver or kidney damage. Now, I demand an answer on moral grounds: '''Why is this study not mentioned in this article?''' I hold a biochemistry degree and a master's degree in medical science and would like to know why this isn't mentioned in the article. | |||
The scientific community is a monolith now and you speak for them? ] (]) 10:24, 15 January 2023 (UTC) | |||
Additionally, Ushijima et al. in the journal <u>Oncology Reports</u> published an article called "<u>Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells</u>" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868501/) which <b>clearly reports epigenetic changes in colon cancer cells,</b> changes which are very likely to suppress cancer development and progression using the body's natural tumor suppression system. This work from these researchers is highly suggestive, just as Dr. Burzynski has stated in on-the-record interviews, that epigenetic modulations in response to the presence of antineoplastons are, in whole or in part, how they fight cancer. | |||
:Please point us to class I evidence published in a reputable peer-reviewed academic journal. It's not a monolith, there are literally hundreds of such journals worldwide. One quality publication will suffice. — ] ] 10:42, 15 January 2023 (UTC) | |||
While this is not absolute proof of antineoplaston therapy's efficacy, it is extremely favorable evidence and analysis, and I would just like to know how anybody could look at these studies and act as if the whole antineoplaston therapy question should just be dismissed as quackery. | |||
Here’s one source: (I have ~20 more to post too) | |||
Misplaced Pages - in fact, anybody - I ask you: why is none of this mentioned in the article on the topic? In fact, why are the staff at Misplaced Pages not seriously disturbed at the lack of research into this topic? How could anybody look at these studies and not demand further investigation? ] (]) 03:09, 22 January 2023 (UTC) | |||
https://doi.org/10.2165/00126839-200304020-00002 ] (]) 05:56, 18 January 2023 (UTC) | |||
:Read ] and ]. We wait until there are favorable secondary sources that collect primary ones. That is also how competent scientists judge those things. Accepting primary studies at face value is naive and amateurish. --] (]) 06:49, 22 January 2023 (UTC) | |||
::I appreciate your reply. | |||
::1. Who said anybody should "just accept" this or that study "at face value"? - nobody, that's who. The point I made is that this is an example of a professional, independent, peer-reviewed clinical trial which produced results that unambiguously suggest that antineoplastons have clinical efficacy. Yes - duh, obviously - it could be a fluke - it's just that, ''without evidence to the contrary'' it is '''unlikely''' to be a fluke. Does such evidence exist, or not? No clinician in their right mind would say that "this single study means we need to start giving patients antineoplastons right away!" ...but no '''objective''' clinician could possibly look at that study and honestly say that this doesn't warrant interest. Given the history of the field any physician or researcher would be PERFECTLY within their rights to look at that study and say "meh, I'll bet it's a fluke - happens all the time," but '''that''' sort of reply is not science. Only follow-up studies that demonstrate no replication of effect WOULD be evidence. A study like that warrants follow up, and that's a plain fact. To ignore it wholesale in an article which is designed precisely to deal with the very controversy of the efficacy of the drugs is NOT objective or neutral. | |||
::2. Misplaced Pages's own policy (the one you linked me to) on Primary Sources (from "Reliable sources") states: | |||
::======= | |||
::"A primary source may be used on Misplaced Pages only to make straightforward, descriptive '''statements of facts''' that can be '''verified by any educated person with access''' to the primary source but without further, specialized knowledge. For example, an article about a musician may cite discographies and track listings published by the record label, and an article about a novel may cite passages to describe the plot, but any interpretation needs a secondary source." | |||
::======= | |||
::And here : | |||
::======= | |||
::'''''Primary''''' sources should NOT <b>normally</b> be used as a basis for biomedical content. This is because primary biomedical literature is exploratory and often not reliable (any given primary source may be contradicted by another). Any text that relies on primary sources should usually have minimal ], <b>only describe conclusions made by the source, and describe these findings so clearly that any editor can check the sourcing without the need for specialist knowledge. Primary sources should never be cited in support of a conclusion that is not clearly made by the authors</b> | |||
::======= | |||
::Mentioning the results of the aforementioned 2015 Ogata et al. study clearly would not violate the explicit, stated policy, and in fact would do wonders for the objectivity of the article. | |||
::3. This article currently says '''verbatim''' that "there is no clinical evidence of the efficacy of these methods." The authors throughout the Wiki article were very careful to be objective and only report the opinions of institutes and bodies that stated that antineoplastons were not effective, instead of making categorical statements of fact or categorically characterizing the entire extent field of evidence as one way or the other. That is objectivity. However, in the aforementioned statement, this standard was dropped and the article makes a categorical statement which is, in fact, false, because the 2015 Ogata et al. study is an exact contradiction to the statement. | |||
::4. I have no serious academic interest, economic incentive or personal conflict on this matter at all. I just care about objectivity and have an interest in healthcare. Surely you're a clinician or scientist of some kind (I would hope) - what exactly IS your view on the 2015 Ogata et al. study? Do you think it was a fluke? | |||
::I apologize for the length of my reply. ] (]) 16:05, 22 January 2023 (UTC) | |||
:::I have an idea of Hobs opinion, but instead I'm going to give you mine. For us encyclopedia editors, Ogata et al is entirely unimportant, because of ] and ]. - ]the ] 16:21, 22 January 2023 (UTC) | |||
::::Uncannily accurate. --] (]) 17:11, 22 January 2023 (UTC) | |||
::::Agree. ''']''' <small>(] - ])</small> 22:13, 24 January 2023 (UTC) | |||
:::Let me explain. When summarising the 2015 Japanese study, you quoted raw survival data. This means that you've disregarded the existence of confounders and, essentially, the entire statistical model. However, the study conclusion reads: "Overall survival was not statistically improved (''p''=0.105) in the AN arm (''n''=32). RFS was not significant (p=0.343)." As you may know, the ] indicates, in lay terms, to what extent the observed outcome can be credited to the studied intervention. Commonly, statistical models require ''p'' not to exceed 0.05 for the results to be considered ]. | |||
:::Here in this study, ''p'' was significantly higher, which essentially means that the observed outcome (e.g., difference in survival) has not been solely due to the intervention (antineoplaston therapy), since other factors have influenced it more strongly. | |||
:::To but it bluntly, the study offers some evidence that antineoplastons are not effective in the studied dose for this type of cancer (although, being an open-label study, its evidence value is anyway low). | |||
:::If you insist on including the paper, I'm ok with summarising it along the lines: ''In a 2015 randomised open-label study carried out in Japan, ] was ineffective as an adjuvant therapy for ] resulting from ].'' — ] ] 17:09, 22 January 2023 (UTC) | |||
::::Your analysis is excellent, and we should definitely not include it for those reasons. ''']''' <small>(] - ])</small> 22:15, 24 January 2023 (UTC) | |||
:::::], did you read the article before proclaiming Kashmirir's analysis excellent? ] (]) 04:31, 17 January 2024 (UTC) | |||
::::::Yes. My personal view: Primary sources with "antineoplastons" as an ''adjuvant'' therapy for ''liver'' cancer were, and remain, irrelevant to the inflated and entirely unsupportable claims by Burzynski for use of his quackery as a magical ''primary'' therapy (in the words of his stans, a cure) for incurable brain cancers, based on nearly half a century of utterly underwhelming results and large numbers of (well documented) dead patients bilked out of vast sums of money. | |||
::::::My Misplaced Pages policy view: Misplaced Pages is not here to blaze the trail in promoting commercial claims where the consensus in the relavant professional community is that tsaid claims are at best nonsense, and at worst entirely fraudulent. | |||
::::::When all the reliable secondary sources show he's a mendacious quack, so do we. ''']''' <small>(] - ])</small> 19:24, 17 January 2024 (UTC) | |||
:::::::It was a simple yes/no question - the 2015 Japanese study - did you read it before proclaiming Kashmirir's analysis excellent or not. Yes, you say. I believe you know what a ] is, and you know that the study that you read met its primary endpoint. And yet you insist an analysis is excellent that '''misrepresented''' that primary endpoint (p=0.037 for CSS) as not ]. That is '''not''' excellent analysis. It seems to me your preconceptions are clouding your judgement. That's the most charitable interpretation of the facts in front of me I can come up with. How do you explain it? I expected the science and data to show Burzynski's work to be without much merit. But what I'm finding so far is multiple extremely flawed criticisms based on falsehoods. One of which has already been acknowledged and fixed. ] (]) 02:10, 18 January 2024 (UTC) | |||
::::1. I'm sorry but did you not ''read'' the rest of the findings section you quoted from??! It's not even five or six sentences long! And the ''very next sentence'' <u>directly</u> after the one you quoted states: | |||
::::'''Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95%CI 43-not calculated) versus 39 months (95%CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively.''' | |||
::::At the risk of being redundant, I will point out that the P-value is below the threshold of 0.05 <u>you</u> selected! Not that p = 0.05 is some "special" threshold - it's just a convention. Many researchers value a p of 0.1, some 0.05, some 0.01 - those are all not uncommon p values. Either way it doesn't matter since you chose the p of 0.05, which you must not have realized the study conclusion <u>did</u> in fact satisfy. Did you not read the paltry few sentences of the article summary? Or are you seriously purposefully distorting the information? (See #3 below) | |||
::::2. The Misplaced Pages policy states: "Any text that relies on primary sources should...'''only describe conclusions made by the source ... Primary sources <u>should never be cited in support of a conclusion that is not clearly made by the authors</u>''' | |||
::::Now, your suggested "summary" is a '''complete''' reversal of the conclusion the study authors reach, which is described in the single sentence - not difficult to read or see - in the "Interpretations" paragraph of the study: '''Antineoplastons (A10 Injection and AS2-1) might be useful as adjunctive therapy in addition to HAI after hepatectomy in colorectal metastases to the liver.''' To include YOUR summary of the article would be a <u>direct</u> violation of the Misplaced Pages guideline you originally invoked! | |||
::::3. Perhaps most telling of all, you either didn't read the paltry few sentences of the article summary, or had more insidious designs. I'm really just quite perplexed. | |||
::::(A) Your "explanation" - which this person "Guy" bizarrely praised as "excellent" - suggested that a summary of the article could be included as ''In a 2015 randomised open-label study carried out in Japan, ] was ineffective as an adjuvant therapy for ] resulting from ].'' | |||
::::Excuse me, but what...the hell? The study was not testing 5-fluorouracil! '''It''' was not the adjuvant! You obviously didn't understand the simple trial! The article was testing ''addition'' of antineoplastons TO a therapeutic HAI (Hepatic Arterial Infusion) of 5-fluorouracil - the 5-fluorouracil is not an antineoplaston and is a ''known chemotherapeutic'' for this adminstration route - which is WHY they were using it in the first place! The <u>antineoplastons</u> were being ''added as adjuvants'' to be tested - BOTH groups got 5-fluoruracil, ONE got the antineoplastons. | |||
::::(B) You obviously didn't understand the study despite it being incredibly simple. You didn't understand what was being tested, didn't know that 5-fluorouracil was not an antineoplaston, didn't know that 5-fluorouracil via HAI was a known chemotherapeutic, and thought that the data suggested 5-fluorouracil was ineffective, when in fact it is KNOWN to be effective, and the data in fact suggested that the antineoplaston WAS effective. I mean, this is just a ridiculous misinterpretation (or something) on your part - I'm sorry. | |||
::::4. While your characterization of a study on basic research as "utterly useless" regarding clinical applications is an absurd exaggeration, it's perfectly legitimate to suggest it doesn't belong in a subsection, perhaps, about clinical results of a trial of the drug. But to call such basic research "utterly useless" is mind-numbingly obtuse - you can't GET to clinical trials without some plausible mechanism or evidence buttressed by basic research. I have no problem not mentioning the known epigenetic activity of antineoplastons in a summary of ''clinical trials'' - but to say it just shouldn't be included '''anywhere in an article''' about Burzynski and his therapy on antineoplastons is asinine. It's a ''known'' effect of the drug in cancerous cell lines and you have huge portions of an article dedicated to - supposedly - objectively analyzing the efficacy, plausibility and suitability of Burzynski's therapy for cancer treatments! To dismiss it as "utterly useless" is absurd! | |||
::::5. I apologize for any overtly rude-sounding aggression but I was just left gobsmacked and dumbfounded by your response. I thought the people who would be editing a Misplaced Pages article about a supposed quack cancer treatment would be highly qualified experts in a closely related field, if not in the field itself. Instead it seems as if you weren't even familiar with a common chemotherapeutic agent, didn't know what kind of medication it was, and were unable to understand a simple article. | |||
::::6. Let me be clear: I have no intention to continuously revisit these posts over and over again, though perhaps I might if I must. I feel I have said enough that needs to be said and the record will show it here. As I said before I have NO serious dog in this fight or conflict of interest, and I even am SUSPICIOUS of Burzynski's therapy myself! 40+ years of antineoplaston existence - you would think - WOULD render something more substantial by now if the therapy is legitimate. In addition, I'm fully aware that Burzynski has registered numerous trials - even many dozens which he suspiciously hasn't published the results of - and in the long run you're bound to get flukes. This study could have been a fluke - BUT THE EVIDENCE does NOT suggest that! To fail to mention this study in the kind of article you've written is simply NOT objective analysis and below the kind of objectivity I would expect from Misplaced Pages, which I have donated to more than once in the past and find an invaluable source of information. The fact is sharing these kinds of controlled trial results CANNOT damage humanity - it will all be part of a record that people are entitled to know about, and to FAIL to mention it is just as bad as promoting false information. | |||
::::Again I'm sorry if this sounded rude but direct confrontation of distortion and confusion can often sound rude when its sole purpose is to get closer to accurate representation of the truth. I really hope you consider this further regardless of whatever decision you make and appreciate your time. I'm sorry again for the length of my writing here but I know of no other way to be thorough and as I said before I hope I do not find myself coming back to this repeatedly since I believe the analysis is self-evident and virtually all that I needed to say has been said here, though it be lengthy. ] (]) 04:45, 27 January 2023 (UTC) | |||
:::::See the second sentence of reply to you. - ]the ] 05:48, 27 January 2023 (UTC) | |||
:::::{{tqb|text=many dozens which he suspiciously hasn't published the results of|by=2600:1700:407B:2810:D80F:D35D:F99E:FBCA|ts=04:45, 27 January 2023 (UTC)|id=c-2600:1700:407B:2810:D80F:D35D:F99E:FBCA-20230127044500-Kashmiri-20230122170900}}{{pb}}Check of mine. Burzynski has published a lot more results than the article lets on. Bon courage . (Though just before finishing this comment, I saw some further edits have been made - hope they are a pleasant surprise.) ] (]) 04:42, 17 January 2024 (UTC) | |||
:::Re. the Ogata study, it's all ] – utterly useless for an article about clinical applications. We don't even need to go into the primary vs secondary debate. — ] ] 17:17, 22 January 2023 (UTC) | |||
::::You grossly misrepresented the findings, ignoring the primary endpoint.{{pb}}{{tqb|text=If you insist on including the paper, I'm ok with summarising it along the lines: ''In a 2015 randomised open-label study carried out in Japan, ] was ineffective as an adjuvant therapy for ] resulting from ].''|by=Kashmiri|ts=17:09, 22 January 2023 (UTC)|id=c-Kashmiri-20230122170900-2600:1700:407B:2810:6015:D9D0:4A7D:D0AE-20230122160500}}{{pb}}That's a deceptive summary. You misrepresented the primary endpoint (p=0.037 for CSS) as not statistically significant when it was. {{pb}}You don't want to walk it back, fine. {{pb}}But I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating ] that I stumbled upon. ] (]) 04:21, 18 January 2024 (UTC) | |||
:::::As other editors have observed, ] is an poor/unreliable source, and simply not usable here. ] (]) 07:46, 18 January 2024 (UTC) | |||
:::::The Findings section contained | |||
:That 2003 ] discusses 12 patients (11 children and an adult), 11 of whom died (for a 92% mortality rate.) The median survival was 7 months. The 12 are a small percentage of the patients treated. It's no wonder that experts have found no evidence antineoplastons work for cancer. Also, at Misplaced Pages, ] are preferred when it comes to medical topics. See ]. ] (]) 06:20, 18 January 2023 (UTC) (edited) | |||
:::::# "Overall survival"- not significant | |||
::From what I understand this doesn't begin to come close to adhering to the practiced protocol. Not looking for debunks of homeopathy or drastically limited range of relevant active components (to this wiki article). Please bridge the gap between any source publication and the article. ] (]) 12:07, 18 January 2023 (UTC) | |||
:::::# "RFS" - not significant | |||
:::Also I'll second the need for secondary sources that indeed do this work of demonstrating relevance already, I'm not sure I follow who responds to what claim here, sorry for any confusion. ] (]) 12:10, 18 January 2023 (UTC) | |||
:::::# "CSS rate" - barely significant at 3.7% | |||
::The 2003 paper states that ''four'' patients were alive as of its writing (out of 12), and two of them were tumour free, so the survival rate was a bit higher than what you provided. But that's irrelevant – the key problem is that this was an observational study with very high risk of bias, not controlled for confounders and where the PIs had an inherent COI. The study, therefore, has zero value in terms of establishing safety or efficacy. — ] ] 02:12, 19 January 2023 (UTC) | |||
:::::# "Cancer recurred" - no statement about significance. | |||
:::::So, we have the ] - there are four outcomes, one of which is barely significant. Because of multiple comparisons, the significances need to be adapted, making the third one not significant either. But the most relevant finding is obviously the first one, overall survival. (Hint: If the treatment tends to kill the patient as well as the cancer, that is not helpful.) That is the one Kashmiri talked about, and there is nothing wrong with that. Can you please stop trying to cram cherry-picked results into the article? --] (]) 08:01, 18 January 2024 (UTC) | |||
::::::Diffs showing cherry-picked results being crammed into the article? I can't stop doing what I haven't started. Back off with the personal attack, eh? {{pb}}The problem is I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating BLP that I stumbled upon. {{pb}}Does MEDRS say anything about the ]? Perhaps it should. {{pb}}But, does V? No. When it comes to BLP violations, ] is what matters. That makes it usable here, even though it's a single study. I notice no one is pushing back on this central point. {{pb}}But more importantly, true or false: Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint, and it DOUBLED. <br>True. Kind of blows apart your whole argument. {{pb}}Kashmiri grossly misrepresented the sole, primary endpoint (p=0.037 for CSS) as not statistically significant when it was. Y'all are defending that. {{pb}}And then K called it basic research - huh? Clinical studies are basic research now? {{pb}}Regarding 3: From the article: <br>{{quote|quote=Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95%CI 43-not calculated) versus 39 months (95%CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively.}} so why do you say 3.7%? "3.7" doesn't even appear in the paper! FR! {{pb}}''BTW, the bulk of the shit-ton of negative info about neoplastons in the article is sourced only to non-MEDRS-compliant sources. If I was keen to make neoplastons look better, I could cut most of the negative info out of the article based on MEDRS. How 'bout we compromise, leave all that in, and take out the false info I'm objecting to? '' ] (]) 08:38, 18 January 2024 (UTC) | |||
:::::::{{tq|Diffs showing cherry-picked results being crammed into the article?}} Aren't you trying to put what you call "Good Evidence for Antineoplaston Efficacy from Japan" into the article? It is ], so it is cherry-picking. Even if we regard only this study, you are cherry-picking the one significant result out of four. | |||
:::::::{{tq|Back off with the personal attack, eh?}} A "personal attack" is something that refers to the person instead of what the person is saying or doing. I referred to what you were saying or doing. That is not a personal attack. | |||
:::::::{{tq|Does MEDRS say anything about the Multiple comparisons problem}} MEDRS does not explicitly mention it, but considering it is part of good practice. If you avoid primary studies like this one, that is a good start avoiding the multiple comparisons problem. | |||
:::::::{{tq|Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint}} Was the "PRE-selected, primary endpoint" published before the result was? I cannot find it. | |||
:::::::{{tq|why do you say 3.7%?}} 3.7% = 0.037. | |||
:::::::{{tq|the bulk of the shit-ton of negative info about neoplastons in the article is sourced only to non-MEDRS-compliant sources}} ] say, {{tq|In an article on a fringe topic, if a notable fringe theory is primarily described by amateurs and self-published texts, verifiable and reliable criticism of the fringe theory need not be published in a peer-reviewed journal.}} --] (]) 10:18, 18 January 2024 (UTC) | |||
::::::::You can't even find a diff showing I called anything "Good Evidence for Antineoplaston Efficacy from Japan," Hob. Or that I tried to put the article you are trying to refer to into the article. So...{{pb}}Your {{tq|Can you please stop trying to cram cherry-picked results into the article?}} when I had done nothing of the sort = false and disparaging but OK, a "not personal" attack, so you're sort of right. ] (]) 13:32, 18 January 2024 (UTC) | |||
:::::::::"Good Evidence for Antineoplaston Efficacy from Japan" is the title of this thread. You are writing contributions to it, and I got the impression that you are supporting the IP that started the thread and trying to get that study cited by the article. | |||
:::::::::So you are not trying to get the Ogata study into the article? Then what are you trying to achieve here by talking about the study? This page is for discussing improvements to the article. It is ]. --] (]) 15:49, 18 January 2024 (UTC) | |||
:::::::::{{Tq|You can't even find a diff showing Or that I tried to put the article you are trying to refer to into the article. So...}} - . ] (]) 18:27, 18 January 2024 (UTC) | |||
== |
=== BLP violation === | ||
Other investigators have been successful in duplicating some of his results. It's my understanding that ] requires removing the false claim that "other investigators have not been successful in duplicating" any of his results. We all know: Contentious material about living persons that is unsourced or ] '''must be removed immediately''' from the article and its talk page, especially if potentially ]. This is obviously poorly sourced as it is contradicted by ] .gov sources. I've pulled it. If anyone want's to revert, I urge a visit to ] as a next, pre-revert step. ] (]) 04:21, 18 January 2024 (UTC) | |||
:Classic ]. Questions of experimental replication are not biographical; you just need a reliable source saying whether the replication has happened (or not). ] (]) 07:48, 18 January 2024 (UTC) | |||
First paragraph of efficacy section states “ While the antineoplaston therapy is marketed as a non-toxic alternative to chemotherapy, it is a form of chemotherapy” | |||
== Oddly, I can't find an NIH publication. == | |||
The citation provided does not support this claim. It does support the subsequent claim of toxicity. | |||
A footnote in a journal article on the Phase III trial that the wipedia article uses as a source: <ref name=HammerICT>{{cite journal|last1=Hammer|first1=Mitchell R.|last2=Jonas|first2=Wayne B.|title=Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons|journal=Integrative Cancer Therapies|date=March 2004|volume=3|issue=1|pages=59–65|doi=10.1177/1534735404263448|pmid=15035877|doi-access=free}}</ref><br> | |||
There is not, from what I’ve seen, anywhere other than this article that antineoplaston is considered a form of chemotherapy. ] (]) 23:43, 3 January 2023 (UTC) | |||
is {{quote|§ See M. R. Hammer, Burzynski antineoplaston case study: conflict issues and recommendations. Office of Alternative Medicine report, '''National Institutes of Health''', 1996; M. Hammer, The management of dispute and judgment process in controversial complementary and alternative medicine research. Office of Alternative Medicine Report, National Institutes of Health, 1996.}}<br> | |||
Has anyone found a copy of it anywhere online? I can't with google. | |||
The article is by Hammer and he is citing his own work ... which I can't find. Curious. Also, he doesn't put it in the References section endnote like all his other sources, but rather in a footnote. Also curious. The resulting procedures - methods of social management of research in controversial areas to allow them to proceed anyway that the reference documents haven't been employed in a subsequent second attempt. Curious as well. ] (]) 04:24, 17 January 2024 (UTC) | |||
:Yep, well spotted. An editor who added this passage more than 10 years ago clearly did not check the source, so feel free to go ahead and rework it. — ] ] 01:08, 4 January 2023 (UTC) | |||
{{Reflist-talk}} | |||
:I added a citation. ] (]) 01:19, 4 January 2023 (UTC) | |||
:WWayne Jonas should not be cited, he's a quackery apologist (e.g. author of a number of papers promoting the entirely refuted nonsense that is homeopathy). ''']''' <small>(] - ])</small> 19:39, 17 January 2024 (UTC) | |||
***CITATION FAILURE> The following citations are deficient of any meaningful information and the sources are not professional and should be removed. David Gorski and Sharon Hill are not notable or remarkabe for any opinion on cancer research and nobody would ever care about their opinions. | |||
::Huh? I am not looking for or seeking to cite "WWayne Jonas" <sic> work in the encyclopedia. And given your recent dubious evaluation of what is "excellent", I'm less interested in what you are sharing, un-prompted and citation-free. I'm looking for M. R. Hammer's '''1996 NIH''' publication, not Hammer and Jonas' 2004 ICT publication, which is obviously readily available at the linked source I provided - <ref name=HammerICT>. Do you have anything helpful to offer about what I'm actually expressing curiosity? ] (]) 02:36, 18 January 2024 (UTC) | |||
David Gorski for Science-Based Medicine. December 12, 2011 Dr. Stanislaw Burzynski, antineoplastons, and the selling of an orphan drug as a cancer cure Quote: " it’s not the concept of "personalized gene-targeted therapy" to which I object. It’s how Burzynski does it and how he corrupts the very concept through his "everything but the kitchen sink" approach to throwing "targeted" therapies at cancer patients willy-nilly without a systematic rationale for picking them or, it seems, any concern for potential adverse reactions due to combining drugs that have not been tested adequately in combination." | |||
:::You kind've are. Wayne Jonas was director of the Office of Alternative Medicine at the time. The OAM (now the NCCIH) is independent from the rest of the NIH, so you probably won't find their reports in the same places as the rest of the NIH's output. It wouldn't be usable on Misplaced Pages anyway. ] (]) 02:52, 18 January 2024 (UTC) | |||
Sharon Hill for The Skeptical Inquirer. January 10, 2014 Burzynski Clinic: A Scientifical Year Of Fail] (]) 18:17, 5 January 2023 (UTC) | |||
::::Thanks for the info. Why wouldn't it be usable with subject matter where MEDRS doesn't apply? ] (]) 04:07, 18 January 2024 (UTC) | |||
::::: ], you wrote: "I am not looking for or citing "WWayne Jonas" <sic> work." Actually you are. Jonas is one of the authors of "Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons". Mitchell R. Hammer, PhD, and Wayne B. Jonas, MD | |||
::::: So Jonas is one of the authors, and, as noted above by ], he also happens to be a promotor of quack medicine. -- ] (]) (''''']''''') 05:46, 18 January 2024 (UTC) | |||
:::::I would be amazed if you got consensus that a report from the OAM is RS even in non medical contexts, let alone for Burzynski-related stuff. The OAM was set up in the first place because Sen. ] was a believer (specifically in antineoplastons and bee pollen therapy) and he set the office up and kept it funded to promote those treatments. The whole thing is a political exercise that has very little to do with science. ] (]) 18:33, 18 January 2024 (UTC) | |||
::::::{{pullquote|quote=If I say 1996+2=2004, then 1996+2=2004.}}- O'Brien ] (]) 07:20, 18 January 2024 (UTC) | |||
== Questionable ] source == | |||
:I'm not sure you understand our sourcing requirements. There is no problem with those. - ]the ] 18:49, 5 January 2023 (UTC) | |||
:Edited. Hope you all agree the edit follows the sources more closely. — ] ] 19:39, 5 January 2023 (UTC) | |||
: By the way, ] certainly ''is'' an authority on cancer therapies. — ] ] 19:42, 5 January 2023 (UTC) | |||
The source https://pubmed.ncbi.nlm.nih.gov/3527634/ should really not be used for anything like a factual claim, as it's ABOUTSELF material - Burzynski's own self-serving statement, with no objective review, and including contentious and likely tendentious claims like "The treatment was free from significant side-effects and resulted in objective response in a number of advanced cancer cases". After half a century, there should be an independent source for this, and almost certainly would be, if it were objectively true. ''']''' <small>(] - ])</small> 19:38, 17 January 2024 (UTC) | |||
== Burzynski == | |||
== Claim of copyright violation == | |||
You make note of the FDA going after him with fines and such, but nothing positive about his treatments.Why?. Maybe posting the people and percentages of people that have been cured. WIKIPEDIA is very biased, and I will not make any type of donation to this organization, since it most likely has made enough from the FDA to put what they wanted into this article. ] (]) 19:42, 4 January 2023 (UTC) | |||
:{{tq|nothing positive about his treatments.Why?}} Because we need reliable sources for that. See ] and ]. --] (]) 21:13, 4 January 2023 (UTC) | |||
: There is no compelling evidence that antineoplastons work for cancer, even after 45 years. Unfortunately, a false and misleading video on Youtube (id = rmxUsAI29fw) (by ) seems to have gotten some attention, with nearly 1.5 million views in about a week. ] (]) 03:11, 8 January 2023 (UTC) | |||
::Ah, that explains the uptick in interest. - ]the ] 13:39, 8 January 2023 (UTC) | |||
:You're basically saying we are biased; not "wikipedia". It is the community that makes these calls. I'd like you to point out a specific instance where we are being unfair with sources, rather than a nonspecific cry of bias. As I see it, you're just mad that the community disagrees with you. Democracy means sometimes you don't get what you want. ] (]) 16:54, 8 January 2023 (UTC) | |||
::Every online community must be standing behind some entity, which in return is moderating its activity. If the community stood by itself, it would be on the "dark web". This web is centralized and every public IP has its legal owner. If Misplaced Pages allows your activity then it agrees to your biases. QED ] (]) 21:32, 18 January 2023 (UTC) | |||
The wording is a bit close, but it is a paraphrase. Rather than deleting it, suggest a reword. ] (]) 02:59, 18 January 2024 (UTC) | |||
I think the biased observed by many of the people interested in this matter stems from the need "for evidence" when there are dozens of video testimony from patients of the doctor, but you allow slanderous terms like "quackery" to be used to label his treatment with no such requirements. In addition, several statements of "facts" supporting criticisms of the doctor's work with "citations" refer back to either irrelevant pages or pages that do not contain the text it says it does. It's quite disconcerting the amount of disinformation on this page and people are right to point it out. If you believe in democracy Cartossin, I'm afraid you're going to find more people that observe this bias on the page and call for it to be changed going forward. ] (]) 09:52, 15 January 2023 (UTC) | |||
:False. It's not a paraphrase. It's copying by JzG contrary to a Misplaced Pages policy with legal considerations. ] / ]. ] (]) 04:13, 18 January 2024 (UTC) | |||
:: It's called plagiarism. Putting it in quotes and attributing it solved the problem. -- ] (]) (''''']''''') 07:17, 18 January 2024 (UTC) | |||
:Now it's more messed up. ''a cancer expert and an FDA official told Reuters'' and ''Reuters said'' aren't the same. ] (]) 04:40, 18 January 2024 (UTC) | |||
::Well, perhaps you should have left well alone, then, since your clumsy attempt to fix the “problem” of reality rejecting Burzynski’s piss therapy seems to be the root cause of all this drama. ''']''' <small>(] - ])</small> 09:06, 22 January 2024 (UTC) | |||
== Talk page vandalism. == | |||
:Anecdote does not equal evidence. All the evidence supports the article. Unsupported testimony is worthless. - ]the ] 09:57, 15 January 2023 (UTC) | |||
:Misplaced Pages is not even a democracy. See ]. --] (]) 10:17, 15 January 2023 (UTC) | |||
Beware removing active discussion. ] (]) 06:49, 18 January 2024 (UTC) | |||
Anecdotes does not equal evidence. Correct. Since when does experimental treatments with numerous documented successes from a licensed medical doctor equal 'quackery'? I'm aware Hob, I was referencing the previous statement. ] (]) 10:22, 15 January 2023 (UTC) | |||
: Now a third time. I was archiving old and inactive content and didn't notice you had left comments in some of them. Now you have restored the whole thing. I'll be more careful with the next try. -- ] (]) (''''']''''') 07:07, 18 January 2024 (UTC) | |||
: To avoid this in the future, don't comment on such old threads. Start a new thread. -- ] (]) (''''']''''') 07:14, 18 January 2024 (UTC) | |||
::Thank you! Such helpful advice. SO kind of you. ] (]) 07:21, 18 January 2024 (UTC) | |||
== Notice == | |||
:Published case series are considered class IV evidence – interesting to read and documenting a clinical practice but virtually worthless in establishing a treatment's efficacy. Do you have anything else to offer beyond case series? — ] ] 10:46, 15 January 2023 (UTC) | |||
{{t|BLP noticeboard}} ] (]) 09:05, 18 January 2024 (UTC) | |||
== Bias == | |||
== Semi-protected edit request on 5 March 2024 == | |||
This page is incredibly biased: Zero effort to present any information on the successes of this doctor's research and treatments. And how incredibly unsuccessful the FDA, Texas Medical Board, et al, have been in their claims against him. This page smells like astro-turfing and that's apparently allowed because it "comes from the community." That's where Misplaced Pages has no integrity. See Cheryl Attkinsson's TedX talk, "Astroturf and manipulation of media messages." Just wondering how much Big Pharma pays "the community" for their input. ] (]) 23:04, 9 January 2023 (UTC) | |||
:I need some clarification here: your first statement implies that people are intentionally not making an effort to contribute to the article, but then you wonder if people are getting paid. If folks are being paid to not contribute to the article, I'm outraged; I can not-contribute to a ''ton'' more articles than I'm currently not contributing to. Is there a recruiter I can talk to?--] (]) 02:55, 10 January 2023 (UTC) | |||
{{edit semi-protected|Burzynski Clinic|answered=yes}} | |||
Totally agree! Where are the success stories? Any credible institution (government or not) will show ALL sides of a case. Slanderous statements with no credibility appear as if authoritative - yet, just sloppy bullying. ] (]) 05:23, 10 January 2023 (UTC) | |||
The article is slanderous. Reliable source : Burzynski documentary. Cancer cure cover up. It’s big business. He’s not a quack. Big $ has all the power to run smeer campaigns on anyone they like. The fda & Texas medical board were so despicable & unashamedly bold in taking him down because of his non invasive EFFECTIVE treatment of cancer. There are so many testimonials court appearances protests & news reports in this 2 part documentary it’s mind blowing. ] (]) 05:57, 5 March 2024 (UTC)<Eric Merola> | |||
:The consensus among all relevant experts and expert bodies is that this is worthless therapy being used as a basis for ]. ] (]) 05:41, 10 January 2023 (UTC) | |||
:{{not done}} That documentary is not a reliable source. Far from it. ] (]) 06:01, 5 March 2024 (UTC) | |||
::Disagree. You made it sound as if there existed strong evidence on antineoplaston's (in)efficacy – yet in reality there's none: no reliable studies of antineoplastons have ever been conducted and/or published. Expert bodies don't call unproven therapies "worthless" but say: "Please generate evidence." Burzynski's fault is not that he uses antineoplastons, but that he promotes them as an effective therapy when there's no evidence, and additionally charges absurd money for it. — ] ] 21:01, 11 January 2023 (UTC) | |||
:::From the article: {{tq|Since the mid-1990s, Burzynski registered some sixty clinical trials of antineoplastons and, in December 2010, a Phase III trial which did not open for patient recruitment. Burzynski has not published full results for any of these.}} That is strong enough evidence on antineoplaston's inefficacy for a {{tq|consensus among all relevant experts}}. If it worked, he would have published by now. --] (]) 21:44, 11 January 2023 (UTC) | |||
::::Exactly. No peer-reviewed publication = no evidence. Note that Class I evidence is normally expected. | |||
::::However, no evidence of efficacy ≠ evidence of inefficacy! — ] ] 22:30, 11 January 2023 (UTC) | |||
:::::We have a failure to find evidence in a situation where finding evidence was to be expected (if efficacious), and we have a consensus among experts. On the other hand, we have anecdotes. The things on the first hand belongs in the article, and the other does not. Then you start talking about mathematical logic. This is pointless nitpicking unrelated to article improvement. --] (]) 08:06, 12 January 2023 (UTC) | |||
::::::I think you fail to understand that no "expert consensus" exists about the treatments' (in)efficacy – precisely because a consensus needs scientific data. Yes, we can make an ''assumption'' (which may actually not be far from truth) that the failure to generate data after so many years of clinical practice, and involving such a high number of patients, may well mean that the treatments are worthless. But in science, we can only say that there's no supporting data; not that they're "proven" to be ineffective. In science, any assertion requires evidence – see ]. | |||
::::::The expert consensus is, more or less, that Burzynski's treatments cannot be recommended in treating cancer. | |||
::::::It's always worth discerning medical science from public health advocacy. Misplaced Pages is the former. — ] ] 10:38, 15 January 2023 (UTC) | |||
:::::::Still unrelated to article improvement. --] (]) 10:54, 15 January 2023 (UTC) | |||
::::::::It's a direct response to your claim of "strong enough evidence on antineoplaston's inefficacy". Unless you don't want other editors respond? — ] ] 11:16, 15 January 2023 (UTC) | |||
:::::::::All I did was respond to your tangent {{tq|However, no evidence of efficacy ≠ evidence of inefficacy}} by pointing out that it was enough to generate a {{tq|consensus among all relevant experts}}. Later you swapped "evidence" and "proof": {{tq|not that they're "proven" to be ineffective}}. Can you please stop doing that - depicting me as a sort of simpleton by arguing against obviously false strawmen as if I had promoted them, and claiming that I {{tq|fail to understand}}? I don't need this, and I will stop responding now. --] (]) 11:50, 15 January 2023 (UTC) | |||
::::::::::Please don't misrepresent the chronology, as yours was not a "response" to mine but preceded it. | |||
::::::::::If my scientific writer conflated ''lack of evidence of efficacy'' with ''evidence of inefficacy'', they'd be losing their job. — ] ] 11:59, 15 January 2023 (UTC) | |||
== Semi-protected edit request on 11 October 2024 == | |||
There most certainly is bias when zero effort was made to share the successes on this page!!! Don’t muddy the very clear and correct statement about BIAS, NapoliRoma! ] (]) 05:47, 10 January 2023 (UTC) | |||
:There are no independently authenticated successes. Only claims made by a man with a financial stake in the outcome and a long history of ethical violations. ''']''' <small>(] - ])</small> 20:04, 11 January 2023 (UTC) | |||
== Patients’ Complaints == | |||
Seems there are no cited patients’ complaints. If there were complaints from any patient, surely the high institutions who claim quackery could cite at least one. ] (]) 05:00, 10 January 2023 (UTC) | |||
:The dead cannot complain. Sometimes the families do. ] (]) 05:02, 10 January 2023 (UTC) | |||
No - families DO complain for unlawful deaths and not one has appeared here! | |||
There are NONE shown. | |||
BTW - Efficacy is never “proven.” It is shown either as statistically evident or not. Statistically, we could look at all of Burzynski’s patients and learn how many were healed and how many were not given certain conditions & stages of cancer. Simple - just do it! Historically stored data is valid to use for such stats of evidence. ] (]) 05:17, 10 January 2023 (UTC) | |||
:The sources are clear: it's harmful quackery that doesn't work. As I understand it, there are no reliable figures and the clinic is cagey about them. ] (]) 05:25, 10 January 2023 (UTC) | |||
No Bon courage, you are wrong. There is NO evidence against this clinic & that is why it is still open and thriving. There are reliable figures and the clinic is NOT cagey about them. If they did not have the numbers to show the evidence of efficacy, they would have closed years ago. Quackery exists in your inability to admit the truth of what happens when a viable cure emerges outside of large pharmaceutical companies’ lucrative reach. ] (]) 05:41, 10 January 2023 (UTC) | |||
: The article does have the complaint from Lola Quinlan. But perhaps OP is on to something in that this article should have more complaints from the patients. and have both chronicled complaints about the Burzynski Clinic. ] (]) 05:43, 10 January 2023 (UTC) | |||
::I'd be wary of detailing individual complaints for the same reason as I'd be wary of individual testimonials. If there was a review covering complaints in general though ... ] (]) 06:03, 10 January 2023 (UTC) | |||
Lola Quinlan had stage 4 cancer. Newer alternative findings about turkey tail cancer may have helped her. Of course without knowing all the details on this one case, we do not know where the truth lies. ] (]) 05:54, 10 January 2023 (UTC) | |||
Statistically, the evidence of successes versus failures could be done on historical data. ] (]) 05:59, 10 January 2023 (UTC) | |||
:It could be, but no good data exists, and in any case it would not be for Misplaced Pages to do that. ] (]) 06:03, 10 January 2023 (UTC) | |||
:The article discusses a number of evidence assessments regarding the Burzynski treatment. But we could probably afford to add more, such as the review by Canadian cancer experts Drs. Blackstein and Bergsagel in the early 1980s. They , "We were left with the impression that either he knows very little about cancer and the responses of different cancers to chemotherapy or else he thinks that we are very stupid and he has tried to hoodwink us." Also I can't immediately find a reliable source for the entire quote but, "We believe that it is unethical to administer unproven agents such as Antineoplastons to patients without satisfying the requirements of the FDA and an ethics committee, that the minimum standards for human experimentation are being met. We also believe that it is immoral to charge patients for this unproven, experimental treatment." ] (]) 06:20, 10 January 2023 (UTC) | |||
::It'd be better to quote academic sources about these supposed therapies rather than personal attacks on the founder in popular media. — ] ] 10:11, 15 January 2023 (UTC) | |||
Totally agree with Kashmiri, criticism needs as much of a foundation in facts as statements in support. ] (]) 10:34, 15 January 2023 (UTC) | |||
== Statistics never PROVES anything == | |||
Change the first sentence that uses the word “proven.” NO TREATMENT has “proof” of efficacy. We do not PROVE a treatment’s success or failure - EVER! | |||
Either the data shows evidence or it does not for efficacy of a treatment. | |||
The evidence could easily be examined by looking at historical data. A neutral party needs to run the numbers. ] (]) 06:15, 10 January 2023 (UTC) | |||
I miswrote… the first sentence has the word, “unproven.” Proof, proven, unproven are all nonsensical words in statistics. We look for evidence! ] (]) 06:17, 10 January 2023 (UTC) | |||
:Medicine is not mathematics and has its own idiom, in which "unproven drug" is a common term for drugs which have no good evidence of worth. ] (]) 06:25, 10 January 2023 (UTC) | |||
::Well.... "Unproven efficacy" or "unapproved medication". There are no "unproven drugs", because a drug is not something that can be "proven". — ] ] 20:41, 11 January 2023 (UTC) | |||
:::How can somebody with such a history here make such a silly statement? - ]the ] 20:44, 11 January 2023 (UTC) | |||
::::Can you explain how will you ''prove a drug''? Use scientific terminology if possible please. — ] ] 10:09, 15 January 2023 (UTC) | |||
== Quackery == | |||
The article cited makes no use of this term which can be characterized as as hominem attack with the intent to undermine the credibility of the doctor in question. The cited article does raise a question as to "how a treatment can be around for 40 years..." etc. Which would be a more apt way of characterizing the debate around the treatment. ] (]) 10:31, 15 January 2023 (UTC) | |||
:The first line of this Misplaced Pages article is supported by the last line of the . ] (]) 21:54, 15 January 2023 (UTC) | |||
== Semi-protected edit request on 17 January 2023 == | |||
{{edit semi-protected|Burzynski Clinic|answered=yes}} | {{edit semi-protected|Burzynski Clinic|answered=yes}} | ||
Under "Antineoplaston Therapy": | |||
The intro to this article contains a lot of bias, can the wording please be seen to to be more informative and less destructive? ] (]) 21:31, 17 January 2023 (UTC) | |||
:] '''Not done:''' it's not clear what changes you want to be made. Please mention the specific changes in a ] and provide a ] if appropriate.<!-- Template:ESp --> ~ ] (]) 21:47, 17 January 2023 (UTC) | |||
Since 2011, the clinic has marketed itself as offering "personalized gene-targeted cancer therapy", which has stirred further controversy. David Gorski argues that the concept of "personalised cancer therapy" is "more of a marketing term than a scientifically meaningful description". According to Gorski, a research oncologist, it appears unlikely that the Burzynski clinic would indeed be able to actually personalise gene-targeting therapies, i.e., "identify who would benefit from specific targeted therapies simply from blood tests," as Burzynski claims, since there are no proven methods to achieve this. Consequently, many reject Burzynski's claim of offering personalized medicine, because in reality his patients are administered untested combinations of various approved and unapproved medications, without a sound rationale for a given combination and without "any concern for potential adverse reactions". | |||
== Quackery 2 == | |||
I suggest removing this paragraph or reworking it entirely. Testing for genetic mutations is the premise of finding the appropriate therapy for many types of cancer. While Dr. Gorski may have a point regarding the semantics, and while his point is somewhat related to the Burzynski Clinic's claims of providing "personalized" services, a reader might draw the conclusion that genetic testing for cancer treatment does not exist. ] (]) 19:05, 11 October 2024 (UTC) | |||
The reference used from the “Antineoplastons: When is enough enough?” Published in the The Lancet Oncology has the below paragraph directly after the author uses the term “Quackery”. | |||
] '''Not done for now''': please establish a ] for this alteration ''']''' using the {{Tlx|Edit semi-protected}} template.<!-- Template:ESp --> ] (]) 20:22, 18 October 2024 (UTC) | |||
“The views expressed here are those of the author and do not necessarily reflect the views of the National Cancer Institute, the National Institutes of Health, the Department of Health and Human Services, or the United States government.“ | |||
== Help I just want to add another film name == | |||
Why is the term quackery used to describe this doctor in the first sentence of this Misplaced Pages article when the source being used is an opinion by the author? ] (]) 05:00, 18 January 2023 (UTC) | |||
I tried to edit this page to add in another film that was directed by Eric Merola with a release date of 2016. The name of the film is (Burzynski: Cancer Cure Cover Up). For some reason I ended up being posted in the M.R. Hammer talk. | |||
:Removed, as it was based on a single opinion piece. — ] ] 09:22, 18 January 2023 (UTC) | |||
I know the subject matter is controversial, however the film I mentioned is clearly mentioned on the IMDb website and I just watched it on the Tubi streaming service. This film clearly exists. Thanks for any help in this matter ] (]) 02:15, 31 December 2024 (UTC) | |||
== Negative Bias == | |||
After reading this Misplaced Pages page, it’s inherently clear that it only includes negative biases towards this doctor. Why do no references include the 100’s of published, reviewed, and cited studies conducted by Dr. Burzynski’s Research Institute? Why is there no discussion of any patients that have been enrolled in his, FDA cleared, Phase II clinical studies that have been cured of cancer included anywhere on this page? Why does the entire “Legal Issues” section omit mentioning that after being summoned by more than 5 grand juries there was no federal indictment proving there was no chargeable criminal activity being performed? The list goes on but I look forward to the response. ] (]) 05:07, 18 January 2023 (UTC) | |||
:Can you point to at least one publication containing results of even one well-designed study? Obviously it should be published in a respectable, peer-reviewed academic journal; not self-published. — ] ] 09:20, 18 January 2023 (UTC) | |||
:You are hoping for a balanced view of this doctor's efforts to cure terminal cancer patients. | |||
:Even if his treatment worked on only 3% of patients, it'd be 'worth a try'. Otherwise you get drawn into the medical establishment's well-established damage limitation strategy. But, it's far higher. So, what now? ] (]) 11:31, 18 January 2023 (UTC)v00n2000 | |||
::As of today, there's no scientific evidence that these treatments work even in 0.0001% of patients. But of course - it's your money, so you decide where to spend it. You're free to give it to a crook, too. — ] ] 01:57, 19 January 2023 (UTC) | |||
== Missing Patents == | |||
This page is missing all patents that Dr. Burzynski obtained for antineoplastons. ] (]) 06:01, 18 January 2023 (UTC) | |||
:]. --] (]) 07:30, 18 January 2023 (UTC) | |||
== Not advocacy == | |||
@]: Please note that ]. Your efforts to add every single instance of negative coverage are making the article rather biased than ]. Are you running a personal crusade against Burzynski? — ] ] 09:07, 18 January 2023 (UTC) | |||
:Indeed. ] (]) 11:33, 18 January 2023 (UTC)v00n2000 | |||
== Partisanship By Way Of Lacking Significance/Missing Sources == | |||
"Legal cases have been brought as a result of the sale of the therapy without regulatory approval." | |||
The guy lives as a result of drinking water, but that does not rise to significance in the context as to why he's seen legal cases. | |||
For the given wording to stand there has to be a demonstration as to how lack of regulatory approval didn't just make him more vulnerable to legal cases. Given he appears to have every right to sell without regulatory approval as far as that segment of the wiki article itself is concerned if you read carefully. That should be made explicit (e.g. with wording such as "opened him up to") or a source should be added that substantiates that it isn't just profit motives masquerading as self deception and concern trolling of the parties bringing cases because the first instinct of the reader is to assume significance. "Where there's smoke there's fire" which is a fallacy. | |||
This extends to wordings such as "The clinic has been the focus of criticism primarily due to". | |||
You'll want to ask sociologists or other experts on intent and unconscious bias when it comes to what is people's reasoning, what is a primary cause. Especially if no demonstrated wrongdoing can be used for soft inference of evidence somebody may or may not have (even with that it'd still be lackluster wording). | |||
I think the section could be fixed by referencing who makes what criticisms, who brings what cases, so that we don't need to worry about "primary reasons" but rather take (and give) people's words, for better or worse. | |||
Or again maybe there is a source that substantiates on the reasons for criticisms, as opposed to there being criticism which is obviously not synonymous with (motivational as opposed to stated) reasons for criticism. But probably more plausible to just fix the wording and not invoke the need to go to sociologist sources that probably don't exist and so on. ] (]) 13:23, 18 January 2023 (UTC) | |||
:Not sure whether these particular lawsuits were related to the regulatory status of his treatments, but certainly, placing unapproved drugs on the market is illegal both in the US and in most of the world, and can certainly be valid grounds for a lawsuit. | |||
:Burzynski apparently tries to game the system by pretending these are all "clinical trials". However, it's illegal to charge trial participants for participation (to the contrary – often people are paid to participate). So I understand that Burzynski claims the hospital charges are for other services, not for antineoplastons. | |||
:This is all quite a contentious practice, and no wonder that when treatments fail, US courts tend to admit lawsuits. | |||
:So I see no problem with the initial statement. — ] ] 18:57, 18 January 2023 (UTC) | |||
== Good Evidence for Antineoplaston Efficacy from Japan == | |||
A 2015 study from Ogata et al. titled "<u>Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer</u>" (https://doi.org/10.1371/journal.pone.0120064) records that in an open label, non-blinded but randomized phase II study '''cancer specific survival rate (CSS) was significantly higher in the antineoplaston arm vs. the control (i.e. non-antineoplaston) arm.''' This study had 65 patients enrolled, with 33 of those in the control group not receiving antineoplaston therapy, and 32 receiving the treatment. Median survival in the antineoplaston group, was, in fact, 67 months vs. 39 months, with a CSS of 60% and 32%, respectively. Furthermore, there were no incidental serious toxicities or apparent liver or kidney damage. Now, I demand an answer on moral grounds: '''Why is this study not mentioned in this article?''' I hold a biochemistry degree and a master's degree in medical science and would like to know why this isn't mentioned in the article. | |||
Additionally, Ushijima et al. in the journal <u>Oncology Reports</u> published an article called "<u>Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells</u>" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868501/) which <b>clearly reports epigenetic changes in colon cancer cells,</b> changes which are very likely to suppress cancer development and progression using the body's natural tumor suppression system. This work from these researchers is highly suggestive, just as Dr. Burzynski has stated in on-the-record interviews, that epigenetic modulations in response to the presence of antineoplastons are, in whole or in part, how they fight cancer. | |||
While this is not absolute proof of antineoplaston therapy's efficacy, it is extremely favorable evidence and analysis, and I would just like to know how anybody could look at these studies and act as if the whole antineoplaston therapy question should just be dismissed as quackery. | |||
Misplaced Pages - in fact, anybody - I ask you: why is none of this mentioned in the article on the topic? In fact, why are the staff at Misplaced Pages not seriously disturbed at the lack of research into this topic? How could anybody look at these studies and not demand further investigation? ] (]) 03:09, 22 January 2023 (UTC) | |||
:Read ] and ]. We wait until there are favorable secondary sources that collect primary ones. That is also how competent scientists judge those things. Accepting primary studies at face value is naive and amateurish. --] (]) 06:49, 22 January 2023 (UTC) | |||
::I appreciate your reply. | |||
::1. Who said anybody should "just accept" this or that study "at face value"? - nobody, that's who. The point I made is that this is an example of a professional, independent, peer-reviewed clinical trial which produced results that unambiguously suggest that antineoplastons have clinical efficacy. Yes - duh, obviously - it could be a fluke - it's just that, ''without evidence to the contrary'' it is '''unlikely''' to be a fluke. Does such evidence exist, or not? No clinician in their right mind would say that "this single study means we need to start giving patients antineoplastons right away!" ...but no '''objective''' clinician could possibly look at that study and honestly say that this doesn't warrant interest. Given the history of the field any physician or researcher would be PERFECTLY within their rights to look at that study and say "meh, I'll bet it's a fluke - happens all the time," but '''that''' sort of reply is not science. Only follow-up studies that demonstrate no replication of effect WOULD be evidence. A study like that warrants follow up, and that's a plain fact. To ignore it wholesale in an article which is designed precisely to deal with the very controversy of the efficacy of the drugs is NOT objective or neutral. | |||
::2. Misplaced Pages's own policy (the one you linked me to) on Primary Sources (from "Reliable sources") states: | |||
::======= | |||
::"A primary source may be used on Misplaced Pages only to make straightforward, descriptive '''statements of facts''' that can be '''verified by any educated person with access''' to the primary source but without further, specialized knowledge. For example, an article about a musician may cite discographies and track listings published by the record label, and an article about a novel may cite passages to describe the plot, but any interpretation needs a secondary source." | |||
::======= | |||
::And here : | |||
::======= | |||
::'''''Primary''''' sources should NOT <b>normally</b> be used as a basis for biomedical content. This is because primary biomedical literature is exploratory and often not reliable (any given primary source may be contradicted by another). Any text that relies on primary sources should usually have minimal ], <b>only describe conclusions made by the source, and describe these findings so clearly that any editor can check the sourcing without the need for specialist knowledge. Primary sources should never be cited in support of a conclusion that is not clearly made by the authors</b> | |||
::======= | |||
::Mentioning the results of the aforementioned 2015 Ogata et al. study clearly would not violate the explicit, stated policy, and in fact would do wonders for the objectivity of the article. | |||
::3. This article currently says '''verbatim''' that "there is no clinical evidence of the efficacy of these methods." The authors throughout the Wiki article were very careful to be objective and only report the opinions of institutes and bodies that stated that antineoplastons were not effective, instead of making categorical statements of fact or categorically characterizing the entire extent field of evidence as one way or the other. That is objectivity. However, in the aforementioned statement, this standard was dropped and the article makes a categorical statement which is, in fact, false, because the 2015 Ogata et al. study is an exact contradiction to the statement. | |||
::4. I have no serious academic interest, economic incentive or personal conflict on this matter at all. I just care about objectivity and have an interest in healthcare. Surely you're a clinician or scientist of some kind (I would hope) - what exactly IS your view on the 2015 Ogata et al. study? Do you think it was a fluke? | |||
::I apologize for the length of my reply. ] (]) 16:05, 22 January 2023 (UTC) |
Latest revision as of 10:49, 31 December 2024
This is the talk page for discussing improvements to the Burzynski Clinic article. This is not a forum for general discussion of the article's subject. |
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: Index, 1, 2, 3, 4, 5, 6, 7, 8Auto-archiving period: 3 months |
The subject of this article is controversial and content may be in dispute. When updating the article, be bold, but not reckless. Feel free to try to improve the article, but don't take it personally if your changes are reversed; instead, come here to the talk page to discuss them. Content must be written from a neutral point of view. Include citations when adding content and consider tagging or removing unsourced information. |
This page is not a forum for general discussion about Burzynski Clinic. Any such comments may be removed or refactored. Please limit discussion to improvement of this article. You may wish to ask factual questions about Burzynski Clinic at the Reference desk. |
This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
This article is rated B-class on Misplaced Pages's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||||||||
|
This article has been mentioned by a media organization:
|
Text and/or other creative content from this version of Burzynski Clinic was copied or moved into Stanislaw Burzynski with this edit on 12:03, 29 August 2012. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted as long as the latter page exists. |
The contentious topics procedure applies to this page. This page is related to pseudoscience and fringe science, which has been designated as a contentious topic. Editors who repeatedly or seriously fail to adhere to the purpose of Misplaced Pages, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page. |
Arbitration Ruling on the Treatment of Pseudoscience
In December of 2006 the Arbitration Committee ruled on guidelines for the presentation of topics as pseudoscience in Misplaced Pages:Requests for arbitration/Pseudoscience. The final decision was as follows:
|
Good Evidence for Antineoplaston Efficacy from Japan
A 2015 study from Ogata et al. titled "Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer" (https://doi.org/10.1371/journal.pone.0120064) records that in an open label, non-blinded but randomized phase II study cancer specific survival rate (CSS) was significantly higher in the antineoplaston arm vs. the control (i.e. non-antineoplaston) arm. This study had 65 patients enrolled, with 33 of those in the control group not receiving antineoplaston therapy, and 32 receiving the treatment. Median survival in the antineoplaston group, was, in fact, 67 months vs. 39 months, with a CSS of 60% and 32%, respectively. Furthermore, there were no incidental serious toxicities or apparent liver or kidney damage. Now, I demand an answer on moral grounds: Why is this study not mentioned in this article? I hold a biochemistry degree and a master's degree in medical science and would like to know why this isn't mentioned in the article.
Additionally, Ushijima et al. in the journal Oncology Reports published an article called "Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868501/) which clearly reports epigenetic changes in colon cancer cells, changes which are very likely to suppress cancer development and progression using the body's natural tumor suppression system. This work from these researchers is highly suggestive, just as Dr. Burzynski has stated in on-the-record interviews, that epigenetic modulations in response to the presence of antineoplastons are, in whole or in part, how they fight cancer.
While this is not absolute proof of antineoplaston therapy's efficacy, it is extremely favorable evidence and analysis, and I would just like to know how anybody could look at these studies and act as if the whole antineoplaston therapy question should just be dismissed as quackery.
Misplaced Pages - in fact, anybody - I ask you: why is none of this mentioned in the article on the topic? In fact, why are the staff at Misplaced Pages not seriously disturbed at the lack of research into this topic? How could anybody look at these studies and not demand further investigation? 2600:1700:407B:2810:153:D9CA:A5FC:2ECC (talk) 03:09, 22 January 2023 (UTC)
- Read WP:MEDRS and WP:PRIMARY. We wait until there are favorable secondary sources that collect primary ones. That is also how competent scientists judge those things. Accepting primary studies at face value is naive and amateurish. --Hob Gadling (talk) 06:49, 22 January 2023 (UTC)
- I appreciate your reply.
- 1. Who said anybody should "just accept" this or that study "at face value"? - nobody, that's who. The point I made is that this is an example of a professional, independent, peer-reviewed clinical trial which produced results that unambiguously suggest that antineoplastons have clinical efficacy. Yes - duh, obviously - it could be a fluke - it's just that, without evidence to the contrary it is unlikely to be a fluke. Does such evidence exist, or not? No clinician in their right mind would say that "this single study means we need to start giving patients antineoplastons right away!" ...but no objective clinician could possibly look at that study and honestly say that this doesn't warrant interest. Given the history of the field any physician or researcher would be PERFECTLY within their rights to look at that study and say "meh, I'll bet it's a fluke - happens all the time," but that sort of reply is not science. Only follow-up studies that demonstrate no replication of effect WOULD be evidence. A study like that warrants follow up, and that's a plain fact. To ignore it wholesale in an article which is designed precisely to deal with the very controversy of the efficacy of the drugs is NOT objective or neutral.
- 2. Misplaced Pages's own policy (the one you linked me to) on Primary Sources (from "Reliable sources") states:
- =======
- "A primary source may be used on Misplaced Pages only to make straightforward, descriptive statements of facts that can be verified by any educated person with access to the primary source but without further, specialized knowledge. For example, an article about a musician may cite discographies and track listings published by the record label, and an article about a novel may cite passages to describe the plot, but any interpretation needs a secondary source."
- =======
- And here :
- =======
- Primary sources should NOT normally be used as a basis for biomedical content. This is because primary biomedical literature is exploratory and often not reliable (any given primary source may be contradicted by another). Any text that relies on primary sources should usually have minimal weight, only describe conclusions made by the source, and describe these findings so clearly that any editor can check the sourcing without the need for specialist knowledge. Primary sources should never be cited in support of a conclusion that is not clearly made by the authors
- =======
- Mentioning the results of the aforementioned 2015 Ogata et al. study clearly would not violate the explicit, stated policy, and in fact would do wonders for the objectivity of the article.
- 3. This article currently says verbatim that "there is no clinical evidence of the efficacy of these methods." The authors throughout the Wiki article were very careful to be objective and only report the opinions of institutes and bodies that stated that antineoplastons were not effective, instead of making categorical statements of fact or categorically characterizing the entire extent field of evidence as one way or the other. That is objectivity. However, in the aforementioned statement, this standard was dropped and the article makes a categorical statement which is, in fact, false, because the 2015 Ogata et al. study is an exact contradiction to the statement.
- 4. I have no serious academic interest, economic incentive or personal conflict on this matter at all. I just care about objectivity and have an interest in healthcare. Surely you're a clinician or scientist of some kind (I would hope) - what exactly IS your view on the 2015 Ogata et al. study? Do you think it was a fluke?
- I apologize for the length of my reply. 2600:1700:407B:2810:6015:D9D0:4A7D:D0AE (talk) 16:05, 22 January 2023 (UTC)
- I have an idea of Hobs opinion, but instead I'm going to give you mine. For us encyclopedia editors, Ogata et al is entirely unimportant, because of WP:RS and WP:MEDRS. - Roxy the dog 16:21, 22 January 2023 (UTC)
- Uncannily accurate. --Hob Gadling (talk) 17:11, 22 January 2023 (UTC)
- Agree. Guy (help! - typo?) 22:13, 24 January 2023 (UTC)
- Let me explain. When summarising the 2015 Japanese study, you quoted raw survival data. This means that you've disregarded the existence of confounders and, essentially, the entire statistical model. However, the study conclusion reads: "Overall survival was not statistically improved (p=0.105) in the AN arm (n=32). RFS was not significant (p=0.343)." As you may know, the p-value indicates, in lay terms, to what extent the observed outcome can be credited to the studied intervention. Commonly, statistical models require p not to exceed 0.05 for the results to be considered statistically significant.
- Here in this study, p was significantly higher, which essentially means that the observed outcome (e.g., difference in survival) has not been solely due to the intervention (antineoplaston therapy), since other factors have influenced it more strongly.
- To but it bluntly, the study offers some evidence that antineoplastons are not effective in the studied dose for this type of cancer (although, being an open-label study, its evidence value is anyway low).
- If you insist on including the paper, I'm ok with summarising it along the lines: In a 2015 randomised open-label study carried out in Japan, 5-fluorouracil was ineffective as an adjuvant therapy for liver metastasis resulting from colorectal cancer. — kashmīrī 17:09, 22 January 2023 (UTC)
- Your analysis is excellent, and we should definitely not include it for those reasons. Guy (help! - typo?) 22:15, 24 January 2023 (UTC)
- JzG, did you read the article before proclaiming Kashmirir's analysis excellent? RudolfoMD (talk) 04:31, 17 January 2024 (UTC)
- Yes. My personal view: Primary sources with "antineoplastons" as an adjuvant therapy for liver cancer were, and remain, irrelevant to the inflated and entirely unsupportable claims by Burzynski for use of his quackery as a magical primary therapy (in the words of his stans, a cure) for incurable brain cancers, based on nearly half a century of utterly underwhelming results and large numbers of (well documented) dead patients bilked out of vast sums of money.
- My Misplaced Pages policy view: Misplaced Pages is not here to blaze the trail in promoting commercial claims where the consensus in the relavant professional community is that tsaid claims are at best nonsense, and at worst entirely fraudulent.
- When all the reliable secondary sources show he's a mendacious quack, so do we. Guy (help! - typo?) 19:24, 17 January 2024 (UTC)
- It was a simple yes/no question - the 2015 Japanese study - did you read it before proclaiming Kashmirir's analysis excellent or not. Yes, you say. I believe you know what a primary endpoint is, and you know that the study that you read met its primary endpoint. And yet you insist an analysis is excellent that misrepresented that primary endpoint (p=0.037 for CSS) as not statistically significant. That is not excellent analysis. It seems to me your preconceptions are clouding your judgement. That's the most charitable interpretation of the facts in front of me I can come up with. How do you explain it? I expected the science and data to show Burzynski's work to be without much merit. But what I'm finding so far is multiple extremely flawed criticisms based on falsehoods. One of which has already been acknowledged and fixed. RudolfoMD (talk) 02:10, 18 January 2024 (UTC)
- JzG, did you read the article before proclaiming Kashmirir's analysis excellent? RudolfoMD (talk) 04:31, 17 January 2024 (UTC)
- 1. I'm sorry but did you not read the rest of the findings section you quoted from??! It's not even five or six sentences long! And the very next sentence directly after the one you quoted states:
- Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95%CI 43-not calculated) versus 39 months (95%CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively.
- At the risk of being redundant, I will point out that the P-value is below the threshold of 0.05 you selected! Not that p = 0.05 is some "special" threshold - it's just a convention. Many researchers value a p of 0.1, some 0.05, some 0.01 - those are all not uncommon p values. Either way it doesn't matter since you chose the p of 0.05, which you must not have realized the study conclusion did in fact satisfy. Did you not read the paltry few sentences of the article summary? Or are you seriously purposefully distorting the information? (See #3 below)
- 2. The Misplaced Pages policy states: "Any text that relies on primary sources should...only describe conclusions made by the source ... Primary sources should never be cited in support of a conclusion that is not clearly made by the authors
- Now, your suggested "summary" is a complete reversal of the conclusion the study authors reach, which is described in the single sentence - not difficult to read or see - in the "Interpretations" paragraph of the study: Antineoplastons (A10 Injection and AS2-1) might be useful as adjunctive therapy in addition to HAI after hepatectomy in colorectal metastases to the liver. To include YOUR summary of the article would be a direct violation of the Misplaced Pages guideline you originally invoked!
- 3. Perhaps most telling of all, you either didn't read the paltry few sentences of the article summary, or had more insidious designs. I'm really just quite perplexed.
- (A) Your "explanation" - which this person "Guy" bizarrely praised as "excellent" - suggested that a summary of the article could be included as In a 2015 randomised open-label study carried out in Japan, 5-fluorouracil was ineffective as an adjuvant therapy for liver metastasis resulting from colorectal cancer.
- Excuse me, but what...the hell? The study was not testing 5-fluorouracil! It was not the adjuvant! You obviously didn't understand the simple trial! The article was testing addition of antineoplastons TO a therapeutic HAI (Hepatic Arterial Infusion) of 5-fluorouracil - the 5-fluorouracil is not an antineoplaston and is a known chemotherapeutic for this adminstration route - which is WHY they were using it in the first place! The antineoplastons were being added as adjuvants to be tested - BOTH groups got 5-fluoruracil, ONE got the antineoplastons.
- (B) You obviously didn't understand the study despite it being incredibly simple. You didn't understand what was being tested, didn't know that 5-fluorouracil was not an antineoplaston, didn't know that 5-fluorouracil via HAI was a known chemotherapeutic, and thought that the data suggested 5-fluorouracil was ineffective, when in fact it is KNOWN to be effective, and the data in fact suggested that the antineoplaston WAS effective. I mean, this is just a ridiculous misinterpretation (or something) on your part - I'm sorry.
- 4. While your characterization of a study on basic research as "utterly useless" regarding clinical applications is an absurd exaggeration, it's perfectly legitimate to suggest it doesn't belong in a subsection, perhaps, about clinical results of a trial of the drug. But to call such basic research "utterly useless" is mind-numbingly obtuse - you can't GET to clinical trials without some plausible mechanism or evidence buttressed by basic research. I have no problem not mentioning the known epigenetic activity of antineoplastons in a summary of clinical trials - but to say it just shouldn't be included anywhere in an article about Burzynski and his therapy on antineoplastons is asinine. It's a known effect of the drug in cancerous cell lines and you have huge portions of an article dedicated to - supposedly - objectively analyzing the efficacy, plausibility and suitability of Burzynski's therapy for cancer treatments! To dismiss it as "utterly useless" is absurd!
- 5. I apologize for any overtly rude-sounding aggression but I was just left gobsmacked and dumbfounded by your response. I thought the people who would be editing a Misplaced Pages article about a supposed quack cancer treatment would be highly qualified experts in a closely related field, if not in the field itself. Instead it seems as if you weren't even familiar with a common chemotherapeutic agent, didn't know what kind of medication it was, and were unable to understand a simple article.
- 6. Let me be clear: I have no intention to continuously revisit these posts over and over again, though perhaps I might if I must. I feel I have said enough that needs to be said and the record will show it here. As I said before I have NO serious dog in this fight or conflict of interest, and I even am SUSPICIOUS of Burzynski's therapy myself! 40+ years of antineoplaston existence - you would think - WOULD render something more substantial by now if the therapy is legitimate. In addition, I'm fully aware that Burzynski has registered numerous trials - even many dozens which he suspiciously hasn't published the results of - and in the long run you're bound to get flukes. This study could have been a fluke - BUT THE EVIDENCE does NOT suggest that! To fail to mention this study in the kind of article you've written is simply NOT objective analysis and below the kind of objectivity I would expect from Misplaced Pages, which I have donated to more than once in the past and find an invaluable source of information. The fact is sharing these kinds of controlled trial results CANNOT damage humanity - it will all be part of a record that people are entitled to know about, and to FAIL to mention it is just as bad as promoting false information.
- Again I'm sorry if this sounded rude but direct confrontation of distortion and confusion can often sound rude when its sole purpose is to get closer to accurate representation of the truth. I really hope you consider this further regardless of whatever decision you make and appreciate your time. I'm sorry again for the length of my writing here but I know of no other way to be thorough and as I said before I hope I do not find myself coming back to this repeatedly since I believe the analysis is self-evident and virtually all that I needed to say has been said here, though it be lengthy. 2600:1700:407B:2810:D80F:D35D:F99E:FBCA (talk) 04:45, 27 January 2023 (UTC)
- See the second sentence of this reply to you. - Roxy the dog 05:48, 27 January 2023 (UTC)
Check these recent edits of mine. Burzynski has published a lot more results than the article lets on. Bon courage insisted on stonewalling when I tried to work with them to correct the false/outdated claim in the article that "that researchers other than Burzynski and his associates have not been successful in duplicating his results". (Though just before finishing this comment, I saw some further edits have been made - hope they are a pleasant surprise.) RudolfoMD (talk) 04:42, 17 January 2024 (UTC)many dozens which he suspiciously hasn't published the results of
— User:2600:1700:407B:2810:D80F:D35D:F99E:FBCA 04:45, 27 January 2023 (UTC)
- Your analysis is excellent, and we should definitely not include it for those reasons. Guy (help! - typo?) 22:15, 24 January 2023 (UTC)
- Re. the Ogata study, it's all basic research – utterly useless for an article about clinical applications. We don't even need to go into the primary vs secondary debate. — kashmīrī 17:17, 22 January 2023 (UTC)
- You grossly misrepresented the findings, ignoring the primary endpoint.
That's a deceptive summary. You misrepresented the primary endpoint (p=0.037 for CSS) as not statistically significant when it was. You don't want to walk it back, fine. But I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating BLP that I stumbled upon. RudolfoMD (talk) 04:21, 18 January 2024 (UTC)If you insist on including the paper, I'm ok with summarising it along the lines: In a 2015 randomised open-label study carried out in Japan, 5-fluorouracil was ineffective as an adjuvant therapy for liver metastasis resulting from colorectal cancer.
— User:Kashmiri 17:09, 22 January 2023 (UTC)- As other editors have observed, PMID:25790229 is an poor/unreliable source, and simply not usable here. Bon courage (talk) 07:46, 18 January 2024 (UTC)
- You grossly misrepresented the findings, ignoring the primary endpoint.
- I have an idea of Hobs opinion, but instead I'm going to give you mine. For us encyclopedia editors, Ogata et al is entirely unimportant, because of WP:RS and WP:MEDRS. - Roxy the dog 16:21, 22 January 2023 (UTC)
- The Findings section contained
- "Overall survival"- not significant
- "RFS" - not significant
- "CSS rate" - barely significant at 3.7%
- "Cancer recurred" - no statement about significance.
- So, we have the Multiple comparisons problem - there are four outcomes, one of which is barely significant. Because of multiple comparisons, the significances need to be adapted, making the third one not significant either. But the most relevant finding is obviously the first one, overall survival. (Hint: If the treatment tends to kill the patient as well as the cancer, that is not helpful.) That is the one Kashmiri talked about, and there is nothing wrong with that. Can you please stop trying to cram cherry-picked results into the article? --Hob Gadling (talk) 08:01, 18 January 2024 (UTC)
- Diffs showing cherry-picked results being crammed into the article? I can't stop doing what I haven't started. Back off with the personal attack, eh? The problem is I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating BLP that I stumbled upon. Does MEDRS say anything about the Multiple comparisons problem? Perhaps it should. But, does V? No. When it comes to BLP violations, wp:V is what matters. That makes it usable here, even though it's a single study. I notice no one is pushing back on this central point. But more importantly, true or false: Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint, and it DOUBLED.
True. Kind of blows apart your whole argument. Kashmiri grossly misrepresented the sole, primary endpoint (p=0.037 for CSS) as not statistically significant when it was. Y'all are defending that. And then K called it basic research - huh? Clinical studies are basic research now? Regarding 3: From the article:
so why do you say 3.7%? "3.7" doesn't even appear in the paper! FR! BTW, the bulk of the shit-ton of negative info about neoplastons in the article is sourced only to non-MEDRS-compliant sources. If I was keen to make neoplastons look better, I could cut most of the negative info out of the article based on MEDRS. How 'bout we compromise, leave all that in, and take out the false info I'm objecting to? RudolfoMD (talk) 08:38, 18 January 2024 (UTC)Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95%CI 43-not calculated) versus 39 months (95%CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively.
Diffs showing cherry-picked results being crammed into the article?
Aren't you trying to put what you call "Good Evidence for Antineoplaston Efficacy from Japan" into the article? It is one primary study out of many, so it is cherry-picking. Even if we regard only this study, you are cherry-picking the one significant result out of four.Back off with the personal attack, eh?
A "personal attack" is something that refers to the person instead of what the person is saying or doing. I referred to what you were saying or doing. That is not a personal attack.Does MEDRS say anything about the Multiple comparisons problem
MEDRS does not explicitly mention it, but considering it is part of good practice. If you avoid primary studies like this one, that is a good start avoiding the multiple comparisons problem.Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint
Was the "PRE-selected, primary endpoint" published before the result was? I cannot find it.why do you say 3.7%?
3.7% = 0.037.the bulk of the shit-ton of negative info about neoplastons in the article is sourced only to non-MEDRS-compliant sources
WP:PARITY say,In an article on a fringe topic, if a notable fringe theory is primarily described by amateurs and self-published texts, verifiable and reliable criticism of the fringe theory need not be published in a peer-reviewed journal.
--Hob Gadling (talk) 10:18, 18 January 2024 (UTC)- You can't even find a diff showing I called anything "Good Evidence for Antineoplaston Efficacy from Japan," Hob. Or that I tried to put the article you are trying to refer to into the article. So...Your
Can you please stop trying to cram cherry-picked results into the article?
when I had done nothing of the sort = false and disparaging but OK, a "not personal" attack, so you're sort of right. RudolfoMD (talk) 13:32, 18 January 2024 (UTC)- "Good Evidence for Antineoplaston Efficacy from Japan" is the title of this thread. You are writing contributions to it, and I got the impression that you are supporting the IP that started the thread and trying to get that study cited by the article.
- So you are not trying to get the Ogata study into the article? Then what are you trying to achieve here by talking about the study? This page is for discussing improvements to the article. It is not a forum. --Hob Gadling (talk) 15:49, 18 January 2024 (UTC)
You can't even find a diff showing Or that I tried to put the article you are trying to refer to into the article. So...
- diff. MrOllie (talk) 18:27, 18 January 2024 (UTC)
- You can't even find a diff showing I called anything "Good Evidence for Antineoplaston Efficacy from Japan," Hob. Or that I tried to put the article you are trying to refer to into the article. So...Your
- Diffs showing cherry-picked results being crammed into the article? I can't stop doing what I haven't started. Back off with the personal attack, eh? The problem is I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating BLP that I stumbled upon. Does MEDRS say anything about the Multiple comparisons problem? Perhaps it should. But, does V? No. When it comes to BLP violations, wp:V is what matters. That makes it usable here, even though it's a single study. I notice no one is pushing back on this central point. But more importantly, true or false: Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint, and it DOUBLED.
- The Findings section contained
BLP violation
Other investigators have been successful in duplicating some of his results. It's my understanding that BLP requires removing the false claim that "other investigators have not been successful in duplicating" any of his results. We all know: Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. This is obviously poorly sourced as it is contradicted by w:V .gov sources. I've pulled it. If anyone want's to revert, I urge a visit to Misplaced Pages:Biographies_of_living_persons/Noticeboard as a next, pre-revert step. RudolfoMD (talk) 04:21, 18 January 2024 (UTC)
- Classic WP:CRYBLP. Questions of experimental replication are not biographical; you just need a reliable source saying whether the replication has happened (or not). Bon courage (talk) 07:48, 18 January 2024 (UTC)
Oddly, I can't find an NIH publication.
A footnote in a journal article on the Phase III trial that the wipedia article uses as a source:
is
§ See M. R. Hammer, Burzynski antineoplaston case study: conflict issues and recommendations. Office of Alternative Medicine report, National Institutes of Health, 1996; M. Hammer, The management of dispute and judgment process in controversial complementary and alternative medicine research. Office of Alternative Medicine Report, National Institutes of Health, 1996.
Has anyone found a copy of it anywhere online? I can't with google.
The article is by Hammer and he is citing his own work ... which I can't find. Curious. Also, he doesn't put it in the References section endnote like all his other sources, but rather in a footnote. Also curious. The resulting procedures - methods of social management of research in controversial areas to allow them to proceed anyway that the reference documents haven't been employed in a subsequent second attempt. Curious as well. RudolfoMD (talk) 04:24, 17 January 2024 (UTC)
References
- Hammer, Mitchell R.; Jonas, Wayne B. (March 2004). "Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons". Integrative Cancer Therapies. 3 (1): 59–65. doi:10.1177/1534735404263448. PMID 15035877.
- WWayne Jonas should not be cited, he's a quackery apologist (e.g. author of a number of papers promoting the entirely refuted nonsense that is homeopathy). Guy (help! - typo?) 19:39, 17 January 2024 (UTC)
- Huh? I am not looking for or seeking to cite "WWayne Jonas" <sic> work in the encyclopedia. And given your recent dubious evaluation of what is "excellent", I'm less interested in what you are sharing, un-prompted and citation-free. I'm looking for M. R. Hammer's 1996 NIH publication, not Hammer and Jonas' 2004 ICT publication, which is obviously readily available at the linked source I provided - <ref name=HammerICT>. Do you have anything helpful to offer about what I'm actually expressing curiosity? RudolfoMD (talk) 02:36, 18 January 2024 (UTC)
- You kind've are. Wayne Jonas was director of the Office of Alternative Medicine at the time. The OAM (now the NCCIH) is independent from the rest of the NIH, so you probably won't find their reports in the same places as the rest of the NIH's output. It wouldn't be usable on Misplaced Pages anyway. MrOllie (talk) 02:52, 18 January 2024 (UTC)
- Thanks for the info. Why wouldn't it be usable with subject matter where MEDRS doesn't apply? RudolfoMD (talk) 04:07, 18 January 2024 (UTC)
- RudolfoMD, you wrote: "I am not looking for or citing "WWayne Jonas" <sic> work." Actually you are. Jonas is one of the authors of "Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons". Mitchell R. Hammer, PhD, and Wayne B. Jonas, MD
- So Jonas is one of the authors, and, as noted above by Guy, he also happens to be a promotor of quack medicine. -- Valjean (talk) (PING me) 05:46, 18 January 2024 (UTC)
- I would be amazed if you got consensus that a report from the OAM is RS even in non medical contexts, let alone for Burzynski-related stuff. The OAM was set up in the first place because Sen. Tom Harkin was a believer (specifically in antineoplastons and bee pollen therapy) and he set the office up and kept it funded to promote those treatments. The whole thing is a political exercise that has very little to do with science. MrOllie (talk) 18:33, 18 January 2024 (UTC)
- Thanks for the info. Why wouldn't it be usable with subject matter where MEDRS doesn't apply? RudolfoMD (talk) 04:07, 18 January 2024 (UTC)
- You kind've are. Wayne Jonas was director of the Office of Alternative Medicine at the time. The OAM (now the NCCIH) is independent from the rest of the NIH, so you probably won't find their reports in the same places as the rest of the NIH's output. It wouldn't be usable on Misplaced Pages anyway. MrOllie (talk) 02:52, 18 January 2024 (UTC)
- Huh? I am not looking for or seeking to cite "WWayne Jonas" <sic> work in the encyclopedia. And given your recent dubious evaluation of what is "excellent", I'm less interested in what you are sharing, un-prompted and citation-free. I'm looking for M. R. Hammer's 1996 NIH publication, not Hammer and Jonas' 2004 ICT publication, which is obviously readily available at the linked source I provided - <ref name=HammerICT>. Do you have anything helpful to offer about what I'm actually expressing curiosity? RudolfoMD (talk) 02:36, 18 January 2024 (UTC)
“ | If I say 1996+2=2004, then 1996+2=2004. | ” |
- O'Brien RudolfoMD (talk) 07:20, 18 January 2024 (UTC)
Questionable WP:ABOUTSELF source
The source https://pubmed.ncbi.nlm.nih.gov/3527634/ should really not be used for anything like a factual claim, as it's ABOUTSELF material - Burzynski's own self-serving statement, with no objective review, and including contentious and likely tendentious claims like "The treatment was free from significant side-effects and resulted in objective response in a number of advanced cancer cases". After half a century, there should be an independent source for this, and almost certainly would be, if it were objectively true. Guy (help! - typo?) 19:38, 17 January 2024 (UTC)
Claim of copyright violation
The wording is a bit close, but it is a paraphrase. Rather than deleting it, suggest a reword. MrOllie (talk) 02:59, 18 January 2024 (UTC)
- False. It's not a paraphrase. It's bloody verbatim copying by JzG contrary to a Misplaced Pages policy with legal considerations. WP:C / COPYRIGHT. RudolfoMD (talk) 04:13, 18 January 2024 (UTC)
- It's called plagiarism. Putting it in quotes and attributing it solved the problem. -- Valjean (talk) (PING me) 07:17, 18 January 2024 (UTC)
- Now it's more messed up. a cancer expert and an FDA official told Reuters and Reuters said aren't the same. RudolfoMD (talk) 04:40, 18 January 2024 (UTC)
- Well, perhaps you should have left well alone, then, since your clumsy attempt to fix the “problem” of reality rejecting Burzynski’s piss therapy seems to be the root cause of all this drama. Guy (help! - typo?) 09:06, 22 January 2024 (UTC)
Talk page vandalism.
Beware Talk page vandalism removing active discussion. RudolfoMD (talk) 06:49, 18 January 2024 (UTC)
- Now a third time. I was archiving old and inactive content and didn't notice you had left comments in some of them. Now you have restored the whole thing. I'll be more careful with the next try. -- Valjean (talk) (PING me) 07:07, 18 January 2024 (UTC)
- To avoid this in the future, don't comment on such old threads. Start a new thread. -- Valjean (talk) (PING me) 07:14, 18 January 2024 (UTC)
- Thank you! Such helpful advice. SO kind of you. RudolfoMD (talk) 07:21, 18 January 2024 (UTC)
Notice
{{BLP noticeboard}} RudolfoMD (talk) 09:05, 18 January 2024 (UTC)
Semi-protected edit request on 5 March 2024
This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
The article is slanderous. Reliable source : Burzynski documentary. Cancer cure cover up. It’s big business. He’s not a quack. Big $ has all the power to run smeer campaigns on anyone they like. The fda & Texas medical board were so despicable & unashamedly bold in taking him down because of his non invasive EFFECTIVE treatment of cancer. There are so many testimonials court appearances protests & news reports in this 2 part documentary it’s mind blowing. Deedssky (talk) 05:57, 5 March 2024 (UTC)<Eric Merola>
- Not done That documentary is not a reliable source. Far from it. Bon courage (talk) 06:01, 5 March 2024 (UTC)
Semi-protected edit request on 11 October 2024
This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
Under "Antineoplaston Therapy":
Since 2011, the clinic has marketed itself as offering "personalized gene-targeted cancer therapy", which has stirred further controversy. David Gorski argues that the concept of "personalised cancer therapy" is "more of a marketing term than a scientifically meaningful description". According to Gorski, a research oncologist, it appears unlikely that the Burzynski clinic would indeed be able to actually personalise gene-targeting therapies, i.e., "identify who would benefit from specific targeted therapies simply from blood tests," as Burzynski claims, since there are no proven methods to achieve this. Consequently, many reject Burzynski's claim of offering personalized medicine, because in reality his patients are administered untested combinations of various approved and unapproved medications, without a sound rationale for a given combination and without "any concern for potential adverse reactions".
I suggest removing this paragraph or reworking it entirely. Testing for genetic mutations is the premise of finding the appropriate therapy for many types of cancer. While Dr. Gorski may have a point regarding the semantics, and while his point is somewhat related to the Burzynski Clinic's claims of providing "personalized" services, a reader might draw the conclusion that genetic testing for cancer treatment does not exist. Ajordan538 (talk) 19:05, 11 October 2024 (UTC)
Not done for now: please establish a consensus for this alteration before using the {{Edit semi-protected}}
template. PianoDan (talk) 20:22, 18 October 2024 (UTC)
Help I just want to add another film name
I tried to edit this page to add in another film that was directed by Eric Merola with a release date of 2016. The name of the film is (Burzynski: Cancer Cure Cover Up). For some reason I ended up being posted in the M.R. Hammer talk. I know the subject matter is controversial, however the film I mentioned is clearly mentioned on the IMDb website and I just watched it on the Tubi streaming service. This film clearly exists. Thanks for any help in this matter Mrgrimfate (talk) 02:15, 31 December 2024 (UTC)
Categories:- Misplaced Pages controversial topics
- Biography articles of living people
- B-Class Skepticism articles
- Mid-importance Skepticism articles
- WikiProject Skepticism articles
- B-Class medicine articles
- Low-importance medicine articles
- Misplaced Pages requested images of medical subjects
- All WikiProject Medicine pages
- B-Class Alternative medicine articles
- B-Class United States articles
- Low-importance United States articles
- B-Class United States articles of Low-importance
- B-Class Texas articles
- Low-importance Texas articles
- WikiProject Texas articles
- Misplaced Pages requested photographs in Texas
- WikiProject United States articles
- Misplaced Pages pages referenced by the press
- Pseudoscience articles under contentious topics procedure